Cofactor Genomics
YC S15St. Louis, US · Founded 2015 · Delaware corporation · 13 employees · 8 known investors
Cofactor Genomics develops predictive diagnostics for cancer immunotherapy using RNA-expression models to characterize tumor microenvironments and predict patient response. The company serves oncology and precision medicine markets by enabling more accurate patient-to-therapy matching.
AI & Machine LearningBiotechHealthtechMedical DevicesDiagnosticsUnited States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (S15)
Cofactor Genomics was founded in 2015 by Dave Messina, Jarret Glasscock, Jarret Glassock, and Jon Armstrong.
DM
Dave Messinain𝕏Founder and Chief Operating Officer2016–2024Dave Messina founded Cofactor Genomics, an RNA and machine learning company that achieved Medicare reimbursement, and has over 25 years of experience in healthcare including prior work on the Human Genome Project. Since 2019, he has led healthcare investments at Pioneer Fund.
JG
Jarret GlasscockinCo-founder · President & CTO
JG
Jarret GlassockCo-founder
JA
Jon ArmstrongCo-founder
Board
MA
MS
Investors · 8
Argonautic VenturesNew York · $5M
Ascension VenturesSaint Louis · $10M – $20M
DCVC (Data Collective)Palo Alto · $5M – $25M
Fifty YearsSan Francisco · $250K – $2M
iSelect FundSt. Louis · $250K – $2M
Menlo VenturesSan Francisco · $1M – $20Mvia Mark Siegel · board
Y CombinatorSan Francisco · $500K
TenOneTen VenturesreportedLos Angeles · $500K – $5M
Reported raises · per SEC filings
Form D private placements$18.8M disclosed across 3 rounds · 2017–2023
▶$1.2MraisedAug 2023 · 2 investors · BiotechnologyRule 506(b)
▶$1.2MraisedAug 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William HagstromDirector
- David MessinaExecutive Officer
- John KuelperExecutive Officer, Director
- Jarret GlasscockExecutive Officer, Director
- Mark SiegelDirector
- Offering amount
- $2M
- Amount sold
- $1.2M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.9MraisedDec 2021 · 9 investors · BiotechnologyRule 506(b)
▶$6.9MraisedDec 2021 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jarret GlasscockExecutive Officer, Director
- David MessinaDirector
- John KuelperExecutive Officer, Director
- William HagstromDirector
- Armen VidianDirector
- Mark SiegelDirector
- Jon ArmstrongDirector
- Offering amount
- $7.1M
- Amount sold
- $6.9M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.7MraisedJun 2017 · 23 investors · BiotechnologyRule 506(b)
▶$10.7MraisedJun 2017 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jarret GlassockExecutive Officer, Director
- Matthew A. OckoDirector
- Jon ArmstrongDirector
- Mark SiegelDirector
- Offering amount
- $15.1M
- Amount sold
- $10.7M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Oup68 shared keywordsOxford University Press publishes research, educational, and reference materials, including reports on reading and children's learning, and reference resources such as its dictionary "Word of the Day." It serves readers, educators, and learners across a wide range of subjects worldwide.
IDbyDNA66 shared keywordsScalable, high throughput DNA sequencing platforms.
Massive Bio57 shared keywordsMassive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.
Abcam48 shared keywordsSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.
Companies competing with Cofactor Genomics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $161.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Cofactor Genomics do?
- Cofactor Genomics develops predictive diagnostics for cancer immunotherapy using RNA-expression models to characterize tumor microenvironments and predict patient response. The company serves oncology and precision medicine markets by enabling more accurate patient-to-therapy matching.
- Who founded Cofactor Genomics?
- Cofactor Genomics was founded by Dave Messina, Jarret Glasscock, Jarret Glassock, Jon Armstrong in 2015.
- Who are Cofactor Genomics's investors?
- Cofactor Genomics's investors include Argonautic Ventures, Ascension Ventures, DCVC (Data Collective), Fifty Years, iSelect Fund, Menlo Ventures, Y Combinator, TenOneTen Ventures.
- How much funding has Cofactor Genomics raised?
- Cofactor Genomics has disclosed $18.8M raised across 3 rounds.
- Where is Cofactor Genomics headquartered?
- Cofactor Genomics is headquartered in St. Louis, US.